Intellectual Property
IP Strategy: Enhanced Brain Delivery of GLP-1s
PATENTS
US 19,638,260
BLOOD-BRAIN BARRIER TRANSMISSION OF GLUCAGON-LIKE PEPTIDE-1 AND GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR AGONISTS
Enhanced delivery of GLP-1 drugs across the blood-brain barrier in order to reduce systemic side effects
Filed: May 5, 2025, and converted to a utility patent on May 4, 2026
IP Strategy: Nose-to-Brain Delivery (N2B NAC)
PATENTS
US 12,594,254
Intranasal Administration of N-acetylcysteine combined with other medicaments
This wide-ranging patent opens the door to unlimited combinations with IN NAC and other drugs using any route of administration.
Issued: April, 2026
US 11,963,939
IN NAC Treatment of Parkinson’s Disease
Method of treatment patent — PD indication
Filed: Jan 13, 2023
US 12,090,130
IN NAC Method of Delivery
Route of administration patent — intranasal delivery method
Filed: Dec 18, 2020
US 11,660,272
Post-Concussion Syndrome Treatment
Method of treatment patent — mTBI / PCS indication
Filed: Dec 2, 2019
PATENT APPLICATIONS
- Multiple continuation patents for IN NAC
- Formulation patents
- Method of treatment patents
PATENT STRATEGY
- Route of administration patents (intranasal delivery)
- Drug-delivery combinations (NAC formulations)
- Method of treatment patents (PD indications)